Gary Ulaner, MD, PhD, FSNMMI, FACNM, of Hoag Family Cancer Institute, highlights 2 new clinical trials for prostate cancer staging and treatment: MIRROR and 177Lu-PNT2002. Hoag is the first site in the world to enroll patients in these trials. MIRROR will investigate piflufolastat F 18 with a whole-body positron emission tomography/computed tomography scan in patients with favorable intermediate-risk prostate cancer to determine its utility in identifying cancer confined to the prostate gland or spread to other areas. ...
RLT
Advertisement
Latest News
The open-label VISON study randomly assigned patients to receive either 177Lu-PSMA-617 plus SoC or SoC alone.
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Dr. Kishan discusses new research presented at the 2024 PSMA Conference.
The first annual PSMA Conference focused on updates in the field of PSMA-based treatments.
Advertisement
Expert Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Advertisement
Advertisement
Roundtables
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
